|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007589,
umls-concept:C0021756,
umls-concept:C0035820,
umls-concept:C0039194,
umls-concept:C0205228,
umls-concept:C0439097,
umls-concept:C1511938,
umls-concept:C1515655,
umls-concept:C1547348,
umls-concept:C1552644,
umls-concept:C1705241,
umls-concept:C1823153,
umls-concept:C2349976
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-7-21
|
|
pubmed:abstractText |
Human Vgamma9Vdelta2 T cells recognize nonpeptidic Ags generated by the 1-deoxy-d-xylulose 5-phosphate (many eubacteria, algae, plants, and Apicomplexa) and mevalonate (eukaryotes, archaebacteria, and certain eubacteria) pathways of isoprenoid synthesis. The potent Vgamma9Vdelta2 T cell reactivity 1) against certain cancer cells or 2) induced by infectious agents indicates that therapeutic augmentations of Vgamma9Vdelta2 T cell activities may be clinically beneficial. The functional characteristics of Vgamma9Vdelta2 T cells from Macaca fascicularis (cynomolgus monkey) are very similar to those from Homo sapiens. We have found that the i.v. administration of nitrogen-containing bisphosphonate or pyrophosphomonoester drugs into cynomolgus monkeys combined with s.c. low-dose (6 x 10(5) U/animal) IL-2 induces a large pool of CD27+ and CD27- effector/memory T cells in the peripheral blood of treated animals. The administration of these drugs in the absence of IL-2 is substantially less effective, indicating the importance of additional exogenous costimuli. Shortly after the costimulatory IL-2 treatment, only gammadelta (but not alphabeta) T cells expressed the CD69 activation marker, indicating that Vgamma9Vdelta2 T lymphocytes are more responsive to low-dose IL-2 than alphabeta T cells. Up to 100-fold increases in the numbers of peripheral blood Vgamma9Vdelta2 T cells were observed in animals receiving the gammadelta stimulatory drug plus IL-2. Moreover, the expanded Vgamma9Vdelta2 T cells were potent Th1 effectors capable of releasing large amounts of IFN-gamma. These results may be relevant for designing novel (or modifying current) immunotherapeutic trials with nitrogen-containing bisphosphonate or pyrophosphomonoester drugs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,3-Diphosphoglycerate,
http://linkedlifedata.com/resource/pubmed/chemical/3-methyl-3,4-epoxybutyl diphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphates,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Epoxy Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Hemiterpenes,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Organophosphorus Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell...,
http://linkedlifedata.com/resource/pubmed/chemical/bromohydrin pyrophosphate,
http://linkedlifedata.com/resource/pubmed/chemical/isopentenyl pyrophosphate,
http://linkedlifedata.com/resource/pubmed/chemical/pamidronate
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
175
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1593-8
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16034098-2,3-Diphosphoglycerate,
pubmed-meshheading:16034098-Animals,
pubmed-meshheading:16034098-Antigens,
pubmed-meshheading:16034098-CD4-CD8 Ratio,
pubmed-meshheading:16034098-Cell Differentiation,
pubmed-meshheading:16034098-Cell Proliferation,
pubmed-meshheading:16034098-Cells, Cultured,
pubmed-meshheading:16034098-Diphosphates,
pubmed-meshheading:16034098-Diphosphonates,
pubmed-meshheading:16034098-Epoxy Compounds,
pubmed-meshheading:16034098-Hemiterpenes,
pubmed-meshheading:16034098-Immunologic Memory,
pubmed-meshheading:16034098-Injections, Intravenous,
pubmed-meshheading:16034098-Injections, Subcutaneous,
pubmed-meshheading:16034098-Interferon-gamma,
pubmed-meshheading:16034098-Interleukin-2,
pubmed-meshheading:16034098-Macaca fascicularis,
pubmed-meshheading:16034098-Organophosphorus Compounds,
pubmed-meshheading:16034098-Receptors, Antigen, T-Cell, gamma-delta,
pubmed-meshheading:16034098-T-Lymphocyte Subsets,
pubmed-meshheading:16034098-Th1 Cells
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
|
|
pubmed:affiliation |
National Institute for Infectious Diseases, Lazzaro Spallanzani, Istituto di Ricerca e Cura a Carattere Scientifico, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
